Goldman Sachs analyst Corinne Johnson initiated coverage of TG Therapeutics (TGTX) with a Neutral rating and $37 price target The firm believes Briuvmi revenue growth will continue to be the key driver of the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX: